Sevabertinib Approved for First-Line Mutated NSCLC
The oral HER2 TKI was previously given accelerated approval in the second line for the indication. Medscape Medical News
Medscape10 SeptMedscape — page 9
167 articlesmedscape.com ↗
Coverage, page 9
page 9 of 9Medscape10 SeptM
US FDA Pauses New Enrollment in Biohaven's Epilepsy Drug Trials
Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental epilepsy drug after rodent... Reuters Health Information
Medscape10 Sept
High Semaglutide Dropout Rates Signal Adherence Challenge
With nearly half of patients discontinuing semaglutide within 12 months — especially younger adults — clinicians face a growing challenge in sustaining long-term treatment. Medscape Medical News
Medscape10 Sept
Routine Liver Markers May Signal Future Cardiovascular Risk
Elevated markers of liver fat, fibrosis, and functional decline are associated with an increased risk for cardiovascular disease in people without clinical liver disease at baseline. Medscape Medical News
Medscape10 Sept
Coma Therapy Tied to Poor Outcomes in Nonconvulsive SE
Patients with nonconvulsive status epilepticus treated with therapeutic coma experience markedly higher rates of complications and mortality than those not receiving the treatment. Medscape Medical News
Medscape10 Sept
Where You Live May Shape Sleep Apnea Outcomes
Patients with obstructive sleep apnea who live in disadvantaged neighborhoods experience more severe sleep-related hypoxemia and have a higher risk for cardiovascular events. Medscape Medical News
Medscape10 SeptM
Once-Monthly PrEP Drug Could Be Manufactured for $3 a Year
The current agreement manufacturer Merck has signed for global access to its once-monthly alimatravir would exclude countries with more than 230,000 new HIV acquisitions a year. Medscape Medical News
Medscape10 Sept